Novartis vet Danny Bar-Zohar leaps back into R&D, taking over the development team at Merck KGaA as Luciano Rossetti steps out

After a brief stint as a biotech investor at Syncona, Novartis vet Danny Bar-Zohar is back in R&D, and he’s taking the lead position at …

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

No­var­tis vet Dan­ny Bar-Zo­har leaps back in­to R&D, tak­ing over the de­vel­op­ment team at Mer­ck KGaA as Lu­ciano Ros­set­ti steps out